GEN-MKT-18-7897-A
Mar 28, 2018 | Blogs, Life Science Research, Lipidomics | 0 comments
Lipidomics research has progressed rapidly in the last decade. Twenty years ago, the determination of the lipid composition of a biological sample required slow and extensive multi-dimensional chromatographic separation and chemical derivatization strategies. Today, in-depth analysis can be performed quickly using high throughput analysis by mass spectrometry.
Advances in mass spectrometry have enabled in-depth lipidomic analyses with unparalleled qualitative and quantitative sensitivity. However, unambiguous identification and quantitation of lipid molecular species in total lipid extracts has proven to be difficult, primarily due to isobaric overlapping isobaric and isomeric species. There are greater than 100,000 lipid molecular species present in a typical biological lipid extract that occupy a narrow mass range (~400-1100 amu), making such overlap a significant problem.
SelexION Technology represents the next technological advance and is uniquely suited for lipidomic research. Using Differential Mobility Separation (DMS) as an upfront orthogonal separation enables the resolution of complex lipid mixtures, effectively addressing the problem of isobaric interferences among different lipid classes and sub-classes.
Key Features of SelexION Technology for Lipid Analysis
SelexION Technology is a planar differential mobility device that separates analytes based on differences in their chemical properties, prior to entering the instrument orifice, thus providing an orthogonal level of selectivity.
Read our technical paper to see how we effectively resolves multiple lipid classes from complex mixtures prior to analysis by mass spectrometry. By removing isobaric and isomeric interferences, lipid analysis by QTRAP systems using SelexION Technology enables more confident identification of lipid molecular species and provides for more accurate relative quantitation by MS/MS.
Warranty expiration is more than an administrative milestone—it is a transition point that can significantly impact instrument uptime, laboratory productivity, operating budgets, and scientific outcomes.
For more than 20 years, the CDCO has supported academic, commercial, and not‑for‑profit drug discovery programs with deep expertise in pharmaceutical lead optimization. Within the bioanalytical group, their role is to enable rapid and reliable decision‑making through quantitative analysis of candidate drugs in biological matrices.
PFAS are increasingly at the center of regulatory change, scientific research, and industry discussion worldwide. As analytical capabilities improve and expectations around environmental responsibility continue to evolve, understanding the role PFAS play, and how they are being addressed, has never been more important. This blog provides an overview of what PFAS are, why they matter, and how responses from regulators and industry are changing.
Posted by
You must be logged in to post a comment.
Share this post with your network